造血干细胞诱导树突状细胞的临床应用

宋现让, 魏玲, 李敏, 王兴武, 薛兴奎, 宋丽华

宋现让, 魏玲, 李敏, 王兴武, 薛兴奎, 宋丽华. 造血干细胞诱导树突状细胞的临床应用[J]. 中国肿瘤临床, 2004, 31(20): 1150-1152.
引用本文: 宋现让, 魏玲, 李敏, 王兴武, 薛兴奎, 宋丽华. 造血干细胞诱导树突状细胞的临床应用[J]. 中国肿瘤临床, 2004, 31(20): 1150-1152.
Song Xianrang, Wei Ling, Li Min, Wang Xingwu, Xue Xingkui, Song Lihua. Clinical Application of Dendritic Cells Induced from Peripheral Blood Stem Cells[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(20): 1150-1152.
Citation: Song Xianrang, Wei Ling, Li Min, Wang Xingwu, Xue Xingkui, Song Lihua. Clinical Application of Dendritic Cells Induced from Peripheral Blood Stem Cells[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(20): 1150-1152.

造血干细胞诱导树突状细胞的临床应用

详细信息
  • 中图分类号: R737.9;R730.51

Clinical Application of Dendritic Cells Induced from Peripheral Blood Stem Cells

  • 摘要: 目的 :探讨回输自动员人外周造血干细胞(PBSC)体外诱导树突状细胞(DCs)治疗乳腺癌患者的可行性。 方法 :采用CS-3000血细胞分离系统分离9例粒细胞集落刺激因子(G-CSF)预动员乳腺癌患者PBSC,在体外经rhGM-CSF、rhIL-4诱导和自体肿瘤细胞提取物刺激后成为成熟DCs,收集并自体回输。用MTT法测定DCs在体内外激活细胞毒性T细胞(CTL)的体外杀伤活性。 结果 :9例患者平均采集1.02×109PBSC,培养后平均收获2.3×108DCs,CD83表达率平均为68.7%。收获DCs的数量是等量未动员全血的57.5倍。在体外自体肿瘤抗原致敏的DCs激活CTL对自体原代培养的肿瘤细胞具有显著的杀伤活性。DC瘤苗自体回输除轻微发烧外,无任何其它不良反应,回输后患者PBMC对自体肿瘤细胞的杀伤活性提高20倍。 结论 :用血细胞分离机分离G-CSF动员肿瘤患者PBSC,在体外诱导制备自体DC瘤苗,回输治疗可提高对自体肿瘤细胞的杀伤活性,而且安全可靠,无明显不良反应。
    Abstract: Objective :To explore the possibility of transfusing dendritic cells (DCs) induced from pre-mobilized human peripheral blood stem cells (PBSC) for therapy of breast cancer patients. Methods :PBSCs were collected from 9 breats cancer patient: who were pre-mobilized with G-CSF dy CS-3000plus Blood Cell Separating System. After 7-8 days'culture in medium containing rhGM-CSF and rhIL-4 and exposure to autologou: cancer cell extracts, they became mature DCs and transfused back to the patients. The killing activity of CTLs activated;mature DCs in vitro and in vivo was determined by using MTT method. Results :The average PBSC number collecting from 9 patients was 1.02x 109. After culture,average 2.3 x108 DCs were harvested averagely.The CB83 positive accounted for 68.7% of DCs.DCS harvested this method was 57.5 folds of the equal volume nonmobilized whole blood. CTL induced by mature DCs killed the cultured autologous primary cancer cells powerfully. After DCs transfusion, the patients only felt slight fever and no other side effects,the cytoto7icity of PBMC increased 20 fold than before. Conclusions
  • [1] Evans JT,Cravens P,Lipsky PE,et al.Differentiation and expan-sion of lentivirus vector-marked dendritic cells derived from hu-man CD34(+)cells[J]. Hum Gene Ther,2000,11(18):2483-2492
    [2] Feng B,Inaba M,Lian Z,et al.Development of mouse dendritic cells from lineage-negativec-kit(low) pluripotent hemopoietic stem cells in vitro[J].Stem Cells,2000,18(1):53-60
    [3] Buchler T,Hajek R,Bourkova L,et al.Generation of antigen-loaded dendritic cells in a serum-free medium using different cy-tokine combinations[J].Vaccine,2003,21(9-10):877-882
    [4] Dilioglou S,Cruse JM,Lewis RE.Costimulatory function of um-bilical cord blood CD14+and CD34+ derived dendritic cells[J].Exp Mol Pathol,2003,75(1):18-33
    [5] Coates PT,Barratt-Boyes SM,Zhang L,et al.Dendritic cell sub-sets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand[J].Blood,2003,102(7):2513-2521
    [6] Hersey P,Menzies SW,Halliday GM,et al.Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma[J].Cancer Immunol Immunother,2004,53(2):125-134
    [7] Marten A,Renoth S,Heinicke T,et al.Allogeneic dendritic cells fused with tumor cells:preclinical results and outcome of a clinical phase 皿 trial in patients with metastatic renal cell carcinoma[J].Hum Gene Ther,2003,14(5):483-494
    [8] Hernando JJ,Park TW,Kuhn WC.Et al.Dendritic cell—based vaccines in breast and gynaecologic cancer [J].Anticancer Res,2003,23(5b):4293-4303
    [9] Morse MA,Clay TM,Colling K,et al.HER2 Dendritic Cell Vaccines[J].Clin Breast Cancer,2003,3(Suppl 4):S164-172
    [10] Ciavarra RP,Brown RR,Holterman DA,et al.Dendritic Cell In-filtration in Colon Cancer[J].J Immunother,2001,24(2):130-137
    [11] Yang AS,Lattime EC.Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses[J].Cancer Res,2003,63(9):2150-2157
计量
  • 文章访问数:  5
  • HTML全文浏览量:  0
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2004-02-18
  • 修回日期:  2004-05-06
  • 发布日期:  2004-10-30

目录

    /

    返回文章
    返回